Wegovy, Zepbound, and Semaglutide: New Obesity Treatment Guidelines for Pharmacologic Therapy

The American College of Physicians (ACP) designated semaglutide (Wegovy) and tirzepatide (Zepbound) as first-line pharmacotherapy for obesity in a new Living Clinical Guideline released by June 23, 2026. The guidance recommends these medications for adults who cannot achieve health goals through lifestyle changes alone, according to reports from Newswise and AJMC.

The ACP’s shift to prioritizing these specific medications marks a transition in how clinicians approach medical weight management. By naming semaglutide and tirzepatide as first-line options, the ACP suggests these drugs should be among the first pharmacological interventions considered for eligible patients, according to Medical News Today.

Which medications are now first-line treatments for obesity?

The ACP Living Clinical Guideline identifies semaglutide and tirzepatide as the primary pharmacological options for managing overweight and obesity. According to AJMC, these medications are favored for their ability to produce significant weight loss compared to older generations of obesity drugs.

Semaglutide, marketed as Wegovy for weight loss, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide, marketed as Zepbound, acts as a dual agonist, targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, according to Medical News Today.

This dual-action mechanism in tirzepatide is often cited in clinical literature as a reason for its high efficacy, though both drugs are now endorsed by the ACP as primary tools for clinicians, according to the Freeman Spogli Institute for International Studies.

Why is the “Living Guideline” format significant?

The ACP utilized a “Living Clinical Guideline” format for these recommendations, which differs from traditional medical guidelines that are updated every few years. According to Newswise, this model allows the ACP to update recommendations in real-time as new clinical trial data becomes available.

This approach is necessary because the field of metabolic medicine is evolving rapidly. The Freeman Spogli Institute for International Studies reports that this format empowers doctors to prescribe pharmacologic therapy based on the most current evidence available rather than waiting for a multi-year review cycle.

By implementing a living document, the ACP can quickly add new medications or adjust dosage recommendations as long-term safety and efficacy data for GLP-1 and GIP medications continue to emerge, according to AJMC.

Who is eligible for these pharmacologic therapies?

The guidelines do not recommend these medications as a standalone replacement for lifestyle changes. According to Newswise, the ACP advises these drugs for patients who have not achieved sufficient weight loss through diet and exercise alone.

Eligible patients typically include those with a high body mass index (BMI) or those with a lower BMI who also suffer from weight-related comorbidities, such as type 2 diabetes or hypertension, according to Medical News Today.

The Indian Practitioner reports that the guidelines are designed to provide a clearer framework for doctors to determine when a patient’s obesity has reached a clinical threshold that requires medication to reduce the risk of cardiovascular disease and other metabolic complications.

How do these recommendations change clinical practice?

Prior to these guidelines, many clinicians followed a tiered approach, starting with older medications that often had lower efficacy or more significant side-effect profiles. The designation of Wegovy and Zepbound as first-line therapies suggests a move toward using the most effective tools earlier in the treatment process, according to AJMC.

This shift may influence how insurance providers and health systems authorize these medications. When a leading professional body like the ACP labels a drug as first-line therapy, it provides a clinical justification for prioritizing those drugs over cheaper, less effective alternatives, according to the Freeman Spogli Institute for International Studies.

However, the guidelines maintain that pharmacotherapy is a component of a broader treatment plan. The ACP emphasizes that medications should be integrated with comprehensive lifestyle modifications to ensure long-term weight maintenance, according to Newswise.

What remains uncertain about these treatments?

While the ACP endorses these drugs, the “living” nature of the guidelines acknowledges that long-term data is still being collected. Medical News Today notes that clinicians must continue to monitor patients for gastrointestinal side effects and other potential long-term risks associated with GLP-1 and GIP receptor agonists.

Additionally, the cost and availability of these medications remain significant barriers for many patients. The ACP guidelines focus on clinical efficacy, but the practical application of these recommendations depends on patient access and insurance coverage, according to the Freeman Spogli Institute for International Studies.